Keyphrases
Amyotrophic Lateral Sclerosis
100%
Randomized Placebo-controlled Trial
100%
Ceftriaxone
100%
Placebo
73%
Hepatobiliary
20%
Amino Acids
13%
Twice Daily
13%
Central Venous Catheter
13%
Functional Decline
13%
Amyotrophic Lateral Sclerosis Functional Rating Scale-revised
13%
Treatment Group
6%
Overexpression
6%
No Significant Difference
6%
Pathophysiology
6%
Gastrointestinal
6%
Family Members
6%
Pharmacokinetics
6%
Adverse Events
6%
Caregivers
6%
Serious Adverse Events
6%
Adaptive Design
6%
Placebo Groups
6%
Canada
6%
Randomized Double-blind Placebo-controlled Study
6%
Symptom Duration
6%
Adult Patients
6%
Home Setting
6%
Glutamate Excitotoxicity
6%
Intention-to-treat
6%
Neurological Disorders
6%
Clinical Site
6%
Clinical Efficacy
6%
Treatment Assignment
6%
Gastrointestinal Side Effects
6%
Disease Onset
6%
Phase III Clinical Trial
6%
Ursodeoxycholic Acid
6%
One-phase
6%
Vital Capacity
6%
Seamless Transition
6%
Efficacy Outcomes
6%
Phase 1/2 Clinical Trial
6%
Permuted Block
6%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Amyotrophic Lateral Sclerosis
100%
Ceftriaxone
100%
Adverse Event
20%
Excitatory Amino Acid
13%
Amino Acid Transporter
13%
Disease
6%
Pathophysiology
6%
Clinical Trial
6%
Symptom
6%
Side Effect
6%
Neurologic Disease
6%
Pharmacokinetics
6%
Glutamic Acid
6%
Excitotoxicity
6%
Placebo-Controlled Study
6%
4 Chloro 3',6' Dimethyl 2,2' Iminodibenzoic Acid
6%
Ursodeoxycholic Acid
6%
Neuroscience
Placebo
100%
Amyotrophic Lateral Sclerosis
100%
Ceftriaxone
100%
Excitatory Amino Acid
13%
Amino Acid Transporter
13%
Glutamic Acid
6%
Pharmacokinetics
6%
Neurological Disorder
6%
Excitotoxicity
6%
Ursodiol
6%
Biochemistry, Genetics and Molecular Biology
Ceftriaxone
100%
Amino Acid Transporter
13%
Clinical Trial
6%
Pharmacokinetics
6%
Animal Model
6%
Ursodeoxycholic Acid
6%
Vital Capacity
6%
Excitotoxicity
6%